睿知中国疾病研究地图
候选清单0

正在招募尤文肉瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

ClinicalTrials.gov 上登记的一项尤文肉瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心首都医科大学附属北京儿童医院Beijing Children's Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06564272,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 12 岁 至 18 岁;性别:不限

    登记记录的入选字段

  2. Currently participating in another therapeutic clinical trial; received any anticancer treatment within 2 weeks or 5 half-lives (whichever is longer) before the start of the study treatment; received whole-brain radiation therapy within 14 days before the start of the study treatment; received stereotactic radiosurgery within 7 days before the start of the study treatment; or received herbal or traditional Chinese medicine for anticancer purposes within 2 weeks before the study treatment;

    排除标准第 7 条

    Persistent toxicity from previous anticancer treatment that has not improved to ≤ Grade 1 (according to CTCAE v5.0), excluding alopecia;

    排除标准第 9 条

  3. Karnofsky performance status (≥16 years) or Lansky performance status (<16 years) score of ≥60%;

    入选标准第 5 条

  4. Patients with at least one measurable lesions according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumors);

    入选标准第 6 条

  5. History of or concurrent other malignancies within the past 5 years;

    排除标准第 3 条

    Hepatitis B surface antigen (HBsAg) positive with HBV-DNA ≥500 IU/mL or 2500 copies/mL; Hepatitis C virus (HCV) antibody positive with HCV RNA ≥200 IU/mL or positive test results; HIV-positive individuals;

    排除标准第 13 条

  6. Female patients who have started menstruating must have a negative pregnancy test;

    入选标准第 9 条

    Fertile patients (e.g., females who have started menstruating or males who have started ejaculating) who do not agree to use contraception (e.g., birth control pills or condoms) during the study and for 6 months after the study ends;

    排除标准第 15 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06564272,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age between 12 and less than 18 years;
  2. Diagnosed with Ewing sarcoma confirmed by histopathological examination;
  3. Patients with locally advanced or metastatic Ewing sarcoma that is unresectable or has failed standard treatment, and for whom no other treatment options are available as assessed by the investigator;
  4. Body weight of ≥30 kg;
  5. Karnofsky performance status (≥16 years) or Lansky performance status (<16 years) score of ≥60%;
  6. Patients with at least one measurable lesions according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumors);
  7. Expected survival of more than 12 weeks;
  8. Sufficient organ and bone marrow function;
  9. Female patients who have started menstruating must have a negative pregnancy test;
  10. The patient and their legal guardians understand and are willing to participate in the trial, and have signed the informed consent form.

排除标准:Exclusion Criteria:

  1. Patients with primary central nervous system tumors;
  2. Presence of central nervous system metastases as diagnosed by imaging;
  3. History of or concurrent other malignancies within the past 5 years;
  4. Gastrointestinal abnormalities;
  5. Cardiovascular or cerebrovascular abnormalities;
  6. Patients who have previously received VEGFR-TKI small molecule treatment;
  7. Currently participating in another therapeutic clinical trial; received any anticancer treatment within 2 weeks or 5 half-lives (whichever is longer) before the start of the study treatment; received whole-brain radiation therapy within 14 days before the start of the study treatment; received stereotactic radiosurgery within 7 days before the start of the study treatment; or received herbal or traditional Chinese medicine for anticancer purposes within 2 weeks before the study treatment;
  8. Underwent major surgery within 2 months before enrollment or have not fully recovered, or plan to undergo surgery during the current study period;
  9. Persistent toxicity from previous anticancer treatment that has not improved to ≤ Grade 1 (according to CTCAE v5.0), excluding alopecia;
  10. Unhealed skin wounds, surgical sites, traumatic sites, severe mucosal ulcers, or fractures;
  11. Uncontrolled significant pleural effusion, ascites, or pericardial effusion;
  12. Active bacterial, viral, or fungal infections; unexplained fever >38.5°C within 2 weeks before enrollment;
  13. Hepatitis B surface antigen (HBsAg) positive with HBV-DNA ≥500 IU/mL or 2500 copies/mL; Hepatitis C virus (HCV) antibody positive with HCV RNA ≥200 IU/mL or positive test results; HIV-positive individuals;
  14. Presence of psychiatric or neurological disorders; or cognitive impairment;
  15. Fertile patients (e.g., females who have started menstruating or males who have started ejaculating) who do not agree to use contraception (e.g., birth control pills or condoms) during the study and for 6 months after the study ends;
  16. Patients with insufficient compliance as evaluated by investigator;
  17. The investigator believes that it is not suitable to patient in this clinical trial.

引自 ClinicalTrials.gov, NCT06564272, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06564272,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06564272